pramipexole IR / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 67 Diseases   30 Trials   30 Trials   1133 News 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pramipexole IR / Generic mfg.
ChiCTR-TRC-07000027: A randomized controlled clinical study of Pramipexole for Parkinson's disease

Completed
4
135
 
Artane oral 1-2mg, tid,+ Mirapexin, 0.25 mg/d at beginning, and add to 1.0 mg/d at the end of the second week; the dose will be added from the second weekend to the eighth week to 4. 5 mg/d(1.5 mg, tid); maintain the dose during 12 weeks and reduce the dose during 1-4weeks ;Artane oral 1-2mg, tid + Madopar, 62.5~500 mg, 2~4 times a day depends on the serious of disease + Mirapexin, the dose is same as group 1 ;Artane oral 1-2mg, tid+ Benserazide-Levodopa (Madopar), oral 62.5~500 mg, 2~4 times a day depends on the serious of the disease
First Affiliated Hospital of Xinjiang Medical University; First Affiliated Hospital of Xinjiang Medical University, Special-purpose fund for Evidence Based Medicine of First Affiliated Hospital of Xinjiang Medical University
Primary Parkinson's disease
 
 
2007-007397-28: Evaluation de la tolérance et de l’acceptabilité de la Rasagiline dans le traitement de la maladie de Parkinson au stade précoce

Ongoing
4
240
Europe
Azilect, Sifrol, Azilect, Sifrol, Azilect, Sifrol
Qualissima
Maladie de Parkinson idiopathique au stade précoceMaladie de Parkinson, numéro de classification MedDRA 10061536
 
 
2012-000801-64: A study of the effects of medication on memory in Parkinson\'s Disease

Ongoing
4
55
Europe
Pramipexole dihydrochloride monohydrate extended release, Ropinirole hydrochloride prolonged release, N/A, Mirapexin extended release various strengths, Requip prolonged release, Mirapexin extended release various strengths, Requip prolonged release
University Hospital of North Staffordshire, Keele University, National Institute for Health Research
Idiopathic Parkinson\'s Disease
 
 
2019-001023-13: PAX-D: Randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression

Ongoing
4
204
Europe
Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg, Tablet, Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg
University of Oxford / Clinical Trials and Research Governance, National Institute for Health Research (NIHR)
Treatment resistant depression, Clinical depression that has not responded to two antidepressant treatments, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-003574-31: Treatment of whiplash by dopamine

Not yet recruiting
4
20
Europe
pramipexole 1 A Farma, Tablet, pramipexole 1A FARMA
University of Copenhagen, jens astrup, Bispebjerg Hospital Dpt Neurology,
whiplash tension-type headache, whiplashtension-type headache, Diseases [C] - Nervous System Diseases [C10]
 
 
ChiCTR2000039050: Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibitor in the treatment of 'Wearing-off' in Patients with Parkinson's disease in China: a multicenter, randomized controlled, open study

Not yet recruiting
4
350
 
adding pramipexole ;adding LCE
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital); The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital), Self-finance
Parkinson's Disease
 
 
ChiCTR2000035733: Multicenter prospective study of accurate diagnosis and intervention strategies for elderly sleep-related movement disorders

Not yet recruiting
4
80
 
pramipexole ;gabapentin ;transcranial magnetic stimulation ;gabapentin and transcranial magnetic stimulation
Fudan University, Huashan Hospital; Fudan University, Huashan Hospital, Shanghai Shenkang Hospital Development Center
geriatric insomnia
 
 
NCT05003648: Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

Recruiting
4
24
Europe, US
Pramipexole, Placebo
Massachusetts General Hospital, European Leukodystrophy Association
Adrenoleukodystrophy, Restless Legs Syndrome
04/25
11/25
APQ-TRD, NCT04936126: Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression

Recruiting
4
150
RoW
Quetiapine, Amantadine, Pramipexole
All India Institute of Medical Sciences, Bhubaneswar, Indian Council of Medical Research
Treatment Resistant Depression
07/24
09/24
NCT06580041: Precision Care for Major Depressive Disorder

Enrolling by invitation
4
150
US
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
University of California, San Francisco
Major Depressive Disorder, Depression, Depressive Disorder, Major
09/29
09/29
2010-019396-29: Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease. Modalita` di somministrazione della Levodopa e del pramipexolo nella malattia di parkinson

Ongoing
3
300
Europe
Tablet, COMTAN, STALEVO*100CPR 50/12,5/200MG, STALEVO*100CPR 100/25/200MG, MIRAPEXIN*30CPR 0,18MG, MIRAPEXIN*30CPR 0,7MG
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE, AIFA (bandi per la ricerca indipendente)
Patients with idiopathic Parkinson's Disease. Pazienti con malattia di Parkinson idiopatica., Diseases [C] - Nervous System Diseases [C10]
 
 
2010-023982-23: A randomized trial administering Minocycline, Acetylsalicylic acid or Pramipexole vs Placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffecive disorder

Not yet recruiting
3
400
Europe
anhydrous minocycline, Mirapex®, Acetylsalicylic acid 500mg, Capsule*, Sebomin 100mg MR Capsules, Mirapex® (pramipexole dihydrochloride) 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg Tablets, Acetylsalicylic acid 500mg
The Stanley Medical Research Institute
schizophrenia or schizoaffecive disorder
 
 
2018-002869-18: Pramipexole for Bipolar Depression (Pax-BD)

Ongoing
3
290
Europe
Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg, Tablet, Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, NIHR HTA programme
Bipolar disorder (BD), A mental disorder that causes periods of depression and periods of abnormally elevated mood., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2022-001563-26: Drug treatment with Pramipexole for lack of interest and motivation in depression. Läkemedelsbehandling med pramipexol vid symptomen bristande intresse och nedsatt motivation vid depression.

Not yet recruiting
3
120
Europe
Pramipexol Stada prolonged-release tablets 0,26 mg, 0,52 mg, 1,05 mg and 2,1 mg, Prolonged-release tablet, Pramipexol Stada prolonged-release tablets
Region Skåne, Vetenskapsrådet, ALF, Kungliga fysiografiska sällskapet, Olle Engkvists Stiftelse, Craafordstiftelsen, Ellen och Henrik Sjöbrings Minnesfond, O.M. Perssons Minnesfond, Hjärnfonden
The effect of nine weeks of treatment with the dopamine agonist Pramipexole in patients with depression with clinically significant anhedonia will be evaluated with symptom rating scales, blood and cerebrospinal fluid samples, neuroimaging, and neuropsychological testing. Thus, this study focuses on patients with substantial anhedonia and these patients are identified through validated assessment scales. Behandlingseffekten av nio veckors behandling med dopaminagonisten pramipexol för patienter med depression med kliniskt signifikant anhedoni kommer att utvärderas med symptomskattningar, blod- och likvorprover, neuroimaging och neuropsykologisk testning. Studien riktar sig alltså till patienter med uttalad anhedoni och dessa patienter identifieras via vedertagna skattningsskalor., The patients treated in this study must have an ongoing depression with clearly lowered interest and decreased motivation (i.e. strong anhedonia). Patienterna som behandlas i denna studie ska ha en pågående depression med tydligt sänkt intresse och minskad motivation (d.v.s. uttalad anhedoni)., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
LONG-PRAXOL, NCT05825235: Long-term Efficacy of Pramipexole in Anhedonic Depression

Recruiting
3
80
Europe
Pramipexole
Region Skane, Lund University
Anhedonia, Depression
10/25
12/25
PRIME-PRAXOL, NCT05355337: Pramipexole for Anhedonic Depression

Recruiting
3
120
Europe
Pramipexole, Placebo
Region Skane, Lund University
Psychiatric Disorders Mood, Anhedonia, Depression
12/26
03/27
NCT04759703: Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

Recruiting
2/3
80
US
Pramipexole, Mirapex, Placebo
Massachusetts General Hospital
Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
02/25
06/25
2008-004943-12: The Rubens Study:A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease

Ongoing
2
320
Europe
Pardoprunox, SLV308, Film-coated tablet, Tablet, Mirapex
Solvay Pharmaceuticals B.V.
Early Stage Parkinson’s Disease
 
 
2014-000140-15: Comparative Study of Oxycodone/Naloxone or Pramipexole for the Treatment of Restless Legs Syndrome on sleep quality recorded by polysomnography Studio sulla qualità del sonno registrata mediante polisonnografia di confronto fra ossicodone/naloxone e pramipexolo nel trattamento della sindrome delle gambe senza riposo

Ongoing
2
60
Europe
oxycodone/naloxone, pramipexole, Prolonged-release tablet, Tablet, Targin ® 5mg/2,5 mg, Targin ® 10mg/5 mg, MIRAPEXIN 0,088 mg, MIRAPEXIN 0,18 mg
Fondazione Neureca Onlus, Fondazione Neureca Onlus
Restless legs syndrome Sindrome delle gambe senza riposo, Restless legs syndrome Sindrome delle gambe senza riposo, Diseases [C] - Nervous System Diseases [C10]
 
 
2007-006271-37: Dopamin agonista pramipexol hatása tinnitusra presbyacusisban

Ongoing
2
40
Europe
Mirapexin, MIRAPEXIN, MIRAPEXIN
Medical and Health Science Center, University of Debrecen Dept. of Otolaryngology
Tinnitus and old age presbycusis.
 
 
2009-010282-23: A randomized, open-label, cross-over study to explore a potential involvement of a dopamine related dysfunction as a mechanism behind bruxism

Ongoing
2
20
Europe
Sifrol, Sifrol
Tandvården SU/Mölndal
Patients with severe oral bruxism according to Polysomnographic cut-off criteria for bruxism: more than 4 bruxism episodes per hour, more than 6 bruxism bursts per episode and/or 25 bruxism bursts per hour of sleep and at least 2 episodes with grinding sounds.
 
 
2019-001907-19: Pramipexole augmentation to target anhedonia in depression - a pilot study Tilläggsbehandling med Pramipexol mot anhedonisymptom vid depression - en pilotstudie

Not yet recruiting
2
15
Europe
Pramipexole Orion 0,26 mg, 0,52 mg, 1,05 mg and 2,1 mg, Prolonged-release tablet, Pramipexole Orion
Region Skåne, the Royal Physiographic Society of Lund, the Söderström-Königska Foundation, the province of Scania (Sweden) state grants (ALF), SUS Donations & Foundations
Depression, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2013-002396-17`ACTRN12620000615987: Does the drug Pramipexole improve the verbal communication ability of stroke patients with impaired language function?

Ongoing
2
40
Europe
Pramipexole, Tablet
Birmingham Community Healthcare NHS Trust, Birmingham Community Healthcare NHS Trust
Gestational Diabetes Mellitus (GDM), Prevention of diabetes
 
 
NCT06269146: Pramipexole to Enhance Social Connections

Recruiting
2
108
US
Pramipexole Pill, Mirapex, Placebo Pill
University of California, San Diego, National Institute of Mental Health (NIMH), New York State Psychiatric Institute
Anxiety Disorders, Anxiety, Depression, Social Disconnection
03/26
03/26
OCD-RT, NCT06611592: Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)

Recruiting
2
48
Europe
Pramipexole 0.088mg/tid, Pramipexole 0.18 mg/tid, Pramipexole 0.35 mg/tid
Clinical Academic Center (2CA-Braga)
Obsessive-Compulsive Disorder
08/28
08/28
NCT03642964: A Study in Patients With Major Depressive Disorder

Active, not recruiting
2
24
US
CTC-501
Chase Therapeutics Corporation
Major Depressive Disorder (MDD)
12/25
12/25
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
OCD-RT, NCT05401019: Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)

Withdrawn
2
52
NA
Pramipexole, Risperidone
Clinical Academic Center (2CA-Braga), University of Minho
Obsessive-Compulsive Disorder
12/26
12/26
ChiCTR-TTRCC-12002751: Clinical pharmacology study of anti-parkinson's drug pramipexole

Completed
1
36
 
Given pramipexole only ;Given pramipexole and metformin simultaneously
Institute of Clinical Pharmacology, Central South University; Institute of Clinical Pharmacology, Central South University, National Natural Science Foundation of China
Parkinson's disease
 
 
ChiCTR-IIR-16008496: Pramipexole hydrochloride tablets in Chinese healthy subjects single/oral medicine after meals on an empty stomach in the cycle of an open, randomized, double cross bioequivalence test

Not yet recruiting
1
56
 
Phase 1 take test preparation on an empty stomach; Phase 2 take control product on an empty stomach ;Phase 1 take control product on an empty stomach; Phase 2 take test preparation on an empty stomach ;Phase 1 take test preparation after meal; Phase 2 take control product after meal ;Phase 1 take control product after meal; Phase 2 take test preparation after meal.
The First Hospital of Jilin University; Nanjing Simcere Dongyuan Pharmaceutical co., LTD, Self-raised Funds
Parkinson's Disease
 
 
NCT04249544: Social Decision Making in Parkinson's Disease

Completed
1
18
US
Pramipexole, Placebo
Vanderbilt University Medical Center, United States Department of Defense
Parkinson Disease
06/22
09/22
NCT06457204: A Study in Healthy People to Compare Two Different Sifrol® Tablets

Completed
1
28
Europe
Pramipexole (from manufacturing site 1), Sifrol® Tabletten, Pramipexole (from manufacturing site 2)
Boehringer Ingelheim
Healthy
08/24
08/24
ChiCTR-IOR-16008394: The clinical trial program of Cong Rongjing in treating early-stage Parkinson's disease

Recruiting
N/A
144
 
Sifrol/XI Ning+compound Cong Rongjing ;Sifrol/XI Ning+placebo
Fujian University of Traditional Chinese Medicine; The third people's Hospital of Fujian University of traditional Chinese Medicine, National Health and Family Planning Commission Research Foundation
Pakinson's Dissease
 
 
ChiCTR1800019942: A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease

Not yet recruiting
N/A
300
 
Zishen Pingchan Granules combined with Pramipexole ;Zishen Pingchan Granules placebo combined with Pramipexole
The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital); The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital), National Key Research and Development Program of China
Parkinson’s Disease
 
 
ChiCTR1800015331: Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease

Recruiting
N/A
150
 
levodopa 4 weeks ;pramipexole 4 weeks ;selegiline 4 weeks
Institute of Psychology, Chinese Academy of Sciences; Peking University Third Hospital, National Natural Science Foundation of China
Parkinson's disease
 
 
ChiCTR1900022534: Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial

Not yet recruiting
N/A
388
 
Patients in the entacapone group will be administered entacapone (Novartis; import drug registration certificate number: H20160680), 10 times per day, 200 mg each time, for 3 weeks. ;Patients in the pramipexole group will be administered pramipexole (Boehringer-Ingelheim; import drug registration certificate number: 20140918) , 3 times per day, 1 mg each time, for 3 weeks.
Geriatric Hospital of Hainan; Geriatric Hospital of Hainan, Self-funded
non-motor symptoms of Parkinson’s disease
 
 
ChiCTR1900021708: Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphi

Not yet recruiting
N/A
160
 
No ;pramipexole
Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University; Brain Hospital Affiliated to Nanjing Medical University, China Natural Science Foundation
Parkinson's Disease
 
 
NCT02994719: Gait Analysis in Neurological Disease

Recruiting
N/A
120
US
Anti-Parkinson medication, Carbidopa/levodopa, pramipexole, ropinirole, amantadine, tolcapone, entacapone, Deep Brain Stimulation
Beth Israel Deaconess Medical Center
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease
06/25
06/25
NCT02220309 / 2008-001966-10: Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)

Enrolling by invitation
N/A
160
US
Pramipexole Oral Tablet
Stanford University
Anxiety, Depression
12/24
04/25
ChiCTR2400087756: Efficacy and safety evaluation of generic and original pramipexole: a real-world study

Completed
N/A
1000
 
NA; NA
Xuanwu Hospital of Capital Medical University; Xuanwu Hospital of Capital Medical University, Project commissioned by the National Healthcare Security Administration(JCS-ZCHT-2023-002)
Parkinson’s disease
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pramipexole IR / Generic mfg.
ChiCTR-TRC-07000027: A randomized controlled clinical study of Pramipexole for Parkinson's disease

Completed
4
135
 
Artane oral 1-2mg, tid,+ Mirapexin, 0.25 mg/d at beginning, and add to 1.0 mg/d at the end of the second week; the dose will be added from the second weekend to the eighth week to 4. 5 mg/d(1.5 mg, tid); maintain the dose during 12 weeks and reduce the dose during 1-4weeks ;Artane oral 1-2mg, tid + Madopar, 62.5~500 mg, 2~4 times a day depends on the serious of disease + Mirapexin, the dose is same as group 1 ;Artane oral 1-2mg, tid+ Benserazide-Levodopa (Madopar), oral 62.5~500 mg, 2~4 times a day depends on the serious of the disease
First Affiliated Hospital of Xinjiang Medical University; First Affiliated Hospital of Xinjiang Medical University, Special-purpose fund for Evidence Based Medicine of First Affiliated Hospital of Xinjiang Medical University
Primary Parkinson's disease
 
 
2007-007397-28: Evaluation de la tolérance et de l’acceptabilité de la Rasagiline dans le traitement de la maladie de Parkinson au stade précoce

Ongoing
4
240
Europe
Azilect, Sifrol, Azilect, Sifrol, Azilect, Sifrol
Qualissima
Maladie de Parkinson idiopathique au stade précoceMaladie de Parkinson, numéro de classification MedDRA 10061536
 
 
2012-000801-64: A study of the effects of medication on memory in Parkinson\'s Disease

Ongoing
4
55
Europe
Pramipexole dihydrochloride monohydrate extended release, Ropinirole hydrochloride prolonged release, N/A, Mirapexin extended release various strengths, Requip prolonged release, Mirapexin extended release various strengths, Requip prolonged release
University Hospital of North Staffordshire, Keele University, National Institute for Health Research
Idiopathic Parkinson\'s Disease
 
 
2019-001023-13: PAX-D: Randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression

Ongoing
4
204
Europe
Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg, Tablet, Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg
University of Oxford / Clinical Trials and Research Governance, National Institute for Health Research (NIHR)
Treatment resistant depression, Clinical depression that has not responded to two antidepressant treatments, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-003574-31: Treatment of whiplash by dopamine

Not yet recruiting
4
20
Europe
pramipexole 1 A Farma, Tablet, pramipexole 1A FARMA
University of Copenhagen, jens astrup, Bispebjerg Hospital Dpt Neurology,
whiplash tension-type headache, whiplashtension-type headache, Diseases [C] - Nervous System Diseases [C10]
 
 
ChiCTR2000039050: Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibitor in the treatment of 'Wearing-off' in Patients with Parkinson's disease in China: a multicenter, randomized controlled, open study

Not yet recruiting
4
350
 
adding pramipexole ;adding LCE
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital); The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital), Self-finance
Parkinson's Disease
 
 
ChiCTR2000035733: Multicenter prospective study of accurate diagnosis and intervention strategies for elderly sleep-related movement disorders

Not yet recruiting
4
80
 
pramipexole ;gabapentin ;transcranial magnetic stimulation ;gabapentin and transcranial magnetic stimulation
Fudan University, Huashan Hospital; Fudan University, Huashan Hospital, Shanghai Shenkang Hospital Development Center
geriatric insomnia
 
 
NCT05003648: Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

Recruiting
4
24
Europe, US
Pramipexole, Placebo
Massachusetts General Hospital, European Leukodystrophy Association
Adrenoleukodystrophy, Restless Legs Syndrome
04/25
11/25
APQ-TRD, NCT04936126: Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression

Recruiting
4
150
RoW
Quetiapine, Amantadine, Pramipexole
All India Institute of Medical Sciences, Bhubaneswar, Indian Council of Medical Research
Treatment Resistant Depression
07/24
09/24
NCT06580041: Precision Care for Major Depressive Disorder

Enrolling by invitation
4
150
US
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
University of California, San Francisco
Major Depressive Disorder, Depression, Depressive Disorder, Major
09/29
09/29
2010-019396-29: Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease. Modalita` di somministrazione della Levodopa e del pramipexolo nella malattia di parkinson

Ongoing
3
300
Europe
Tablet, COMTAN, STALEVO*100CPR 50/12,5/200MG, STALEVO*100CPR 100/25/200MG, MIRAPEXIN*30CPR 0,18MG, MIRAPEXIN*30CPR 0,7MG
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE, AIFA (bandi per la ricerca indipendente)
Patients with idiopathic Parkinson's Disease. Pazienti con malattia di Parkinson idiopatica., Diseases [C] - Nervous System Diseases [C10]
 
 
2010-023982-23: A randomized trial administering Minocycline, Acetylsalicylic acid or Pramipexole vs Placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffecive disorder

Not yet recruiting
3
400
Europe
anhydrous minocycline, Mirapex®, Acetylsalicylic acid 500mg, Capsule*, Sebomin 100mg MR Capsules, Mirapex® (pramipexole dihydrochloride) 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.5 mg Tablets, Acetylsalicylic acid 500mg
The Stanley Medical Research Institute
schizophrenia or schizoaffecive disorder
 
 
2018-002869-18: Pramipexole for Bipolar Depression (Pax-BD)

Ongoing
3
290
Europe
Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg, Tablet, Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, NIHR HTA programme
Bipolar disorder (BD), A mental disorder that causes periods of depression and periods of abnormally elevated mood., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2022-001563-26: Drug treatment with Pramipexole for lack of interest and motivation in depression. Läkemedelsbehandling med pramipexol vid symptomen bristande intresse och nedsatt motivation vid depression.

Not yet recruiting
3
120
Europe
Pramipexol Stada prolonged-release tablets 0,26 mg, 0,52 mg, 1,05 mg and 2,1 mg, Prolonged-release tablet, Pramipexol Stada prolonged-release tablets
Region Skåne, Vetenskapsrådet, ALF, Kungliga fysiografiska sällskapet, Olle Engkvists Stiftelse, Craafordstiftelsen, Ellen och Henrik Sjöbrings Minnesfond, O.M. Perssons Minnesfond, Hjärnfonden
The effect of nine weeks of treatment with the dopamine agonist Pramipexole in patients with depression with clinically significant anhedonia will be evaluated with symptom rating scales, blood and cerebrospinal fluid samples, neuroimaging, and neuropsychological testing. Thus, this study focuses on patients with substantial anhedonia and these patients are identified through validated assessment scales. Behandlingseffekten av nio veckors behandling med dopaminagonisten pramipexol för patienter med depression med kliniskt signifikant anhedoni kommer att utvärderas med symptomskattningar, blod- och likvorprover, neuroimaging och neuropsykologisk testning. Studien riktar sig alltså till patienter med uttalad anhedoni och dessa patienter identifieras via vedertagna skattningsskalor., The patients treated in this study must have an ongoing depression with clearly lowered interest and decreased motivation (i.e. strong anhedonia). Patienterna som behandlas i denna studie ska ha en pågående depression med tydligt sänkt intresse och minskad motivation (d.v.s. uttalad anhedoni)., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
LONG-PRAXOL, NCT05825235: Long-term Efficacy of Pramipexole in Anhedonic Depression

Recruiting
3
80
Europe
Pramipexole
Region Skane, Lund University
Anhedonia, Depression
10/25
12/25
PRIME-PRAXOL, NCT05355337: Pramipexole for Anhedonic Depression

Recruiting
3
120
Europe
Pramipexole, Placebo
Region Skane, Lund University
Psychiatric Disorders Mood, Anhedonia, Depression
12/26
03/27
NCT04759703: Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

Recruiting
2/3
80
US
Pramipexole, Mirapex, Placebo
Massachusetts General Hospital
Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
02/25
06/25
2008-004943-12: The Rubens Study:A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease

Ongoing
2
320
Europe
Pardoprunox, SLV308, Film-coated tablet, Tablet, Mirapex
Solvay Pharmaceuticals B.V.
Early Stage Parkinson’s Disease
 
 
2014-000140-15: Comparative Study of Oxycodone/Naloxone or Pramipexole for the Treatment of Restless Legs Syndrome on sleep quality recorded by polysomnography Studio sulla qualità del sonno registrata mediante polisonnografia di confronto fra ossicodone/naloxone e pramipexolo nel trattamento della sindrome delle gambe senza riposo

Ongoing
2
60
Europe
oxycodone/naloxone, pramipexole, Prolonged-release tablet, Tablet, Targin ® 5mg/2,5 mg, Targin ® 10mg/5 mg, MIRAPEXIN 0,088 mg, MIRAPEXIN 0,18 mg
Fondazione Neureca Onlus, Fondazione Neureca Onlus
Restless legs syndrome Sindrome delle gambe senza riposo, Restless legs syndrome Sindrome delle gambe senza riposo, Diseases [C] - Nervous System Diseases [C10]
 
 
2007-006271-37: Dopamin agonista pramipexol hatása tinnitusra presbyacusisban

Ongoing
2
40
Europe
Mirapexin, MIRAPEXIN, MIRAPEXIN
Medical and Health Science Center, University of Debrecen Dept. of Otolaryngology
Tinnitus and old age presbycusis.
 
 
2009-010282-23: A randomized, open-label, cross-over study to explore a potential involvement of a dopamine related dysfunction as a mechanism behind bruxism

Ongoing
2
20
Europe
Sifrol, Sifrol
Tandvården SU/Mölndal
Patients with severe oral bruxism according to Polysomnographic cut-off criteria for bruxism: more than 4 bruxism episodes per hour, more than 6 bruxism bursts per episode and/or 25 bruxism bursts per hour of sleep and at least 2 episodes with grinding sounds.
 
 
2019-001907-19: Pramipexole augmentation to target anhedonia in depression - a pilot study Tilläggsbehandling med Pramipexol mot anhedonisymptom vid depression - en pilotstudie

Not yet recruiting
2
15
Europe
Pramipexole Orion 0,26 mg, 0,52 mg, 1,05 mg and 2,1 mg, Prolonged-release tablet, Pramipexole Orion
Region Skåne, the Royal Physiographic Society of Lund, the Söderström-Königska Foundation, the province of Scania (Sweden) state grants (ALF), SUS Donations & Foundations
Depression, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2013-002396-17`ACTRN12620000615987: Does the drug Pramipexole improve the verbal communication ability of stroke patients with impaired language function?

Ongoing
2
40
Europe
Pramipexole, Tablet
Birmingham Community Healthcare NHS Trust, Birmingham Community Healthcare NHS Trust
Gestational Diabetes Mellitus (GDM), Prevention of diabetes
 
 
NCT06269146: Pramipexole to Enhance Social Connections

Recruiting
2
108
US
Pramipexole Pill, Mirapex, Placebo Pill
University of California, San Diego, National Institute of Mental Health (NIMH), New York State Psychiatric Institute
Anxiety Disorders, Anxiety, Depression, Social Disconnection
03/26
03/26
OCD-RT, NCT06611592: Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)

Recruiting
2
48
Europe
Pramipexole 0.088mg/tid, Pramipexole 0.18 mg/tid, Pramipexole 0.35 mg/tid
Clinical Academic Center (2CA-Braga)
Obsessive-Compulsive Disorder
08/28
08/28
NCT03642964: A Study in Patients With Major Depressive Disorder

Active, not recruiting
2
24
US
CTC-501
Chase Therapeutics Corporation
Major Depressive Disorder (MDD)
12/25
12/25
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
OCD-RT, NCT05401019: Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)

Withdrawn
2
52
NA
Pramipexole, Risperidone
Clinical Academic Center (2CA-Braga), University of Minho
Obsessive-Compulsive Disorder
12/26
12/26
ChiCTR-TTRCC-12002751: Clinical pharmacology study of anti-parkinson's drug pramipexole

Completed
1
36
 
Given pramipexole only ;Given pramipexole and metformin simultaneously
Institute of Clinical Pharmacology, Central South University; Institute of Clinical Pharmacology, Central South University, National Natural Science Foundation of China
Parkinson's disease
 
 
ChiCTR-IIR-16008496: Pramipexole hydrochloride tablets in Chinese healthy subjects single/oral medicine after meals on an empty stomach in the cycle of an open, randomized, double cross bioequivalence test

Not yet recruiting
1
56
 
Phase 1 take test preparation on an empty stomach; Phase 2 take control product on an empty stomach ;Phase 1 take control product on an empty stomach; Phase 2 take test preparation on an empty stomach ;Phase 1 take test preparation after meal; Phase 2 take control product after meal ;Phase 1 take control product after meal; Phase 2 take test preparation after meal.
The First Hospital of Jilin University; Nanjing Simcere Dongyuan Pharmaceutical co., LTD, Self-raised Funds
Parkinson's Disease
 
 
NCT04249544: Social Decision Making in Parkinson's Disease

Completed
1
18
US
Pramipexole, Placebo
Vanderbilt University Medical Center, United States Department of Defense
Parkinson Disease
06/22
09/22
NCT06457204: A Study in Healthy People to Compare Two Different Sifrol® Tablets

Completed
1
28
Europe
Pramipexole (from manufacturing site 1), Sifrol® Tabletten, Pramipexole (from manufacturing site 2)
Boehringer Ingelheim
Healthy
08/24
08/24
ChiCTR-IOR-16008394: The clinical trial program of Cong Rongjing in treating early-stage Parkinson's disease

Recruiting
N/A
144
 
Sifrol/XI Ning+compound Cong Rongjing ;Sifrol/XI Ning+placebo
Fujian University of Traditional Chinese Medicine; The third people's Hospital of Fujian University of traditional Chinese Medicine, National Health and Family Planning Commission Research Foundation
Pakinson's Dissease
 
 
ChiCTR1800019942: A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Pramipexole in the treatment of Depression in Parkinson’s Disease

Not yet recruiting
N/A
300
 
Zishen Pingchan Granules combined with Pramipexole ;Zishen Pingchan Granules placebo combined with Pramipexole
The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital); The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital), National Key Research and Development Program of China
Parkinson’s Disease
 
 
ChiCTR1800015331: Dopaminergic Mechanisms of Temporal Working Memory in Parkinson's Disease

Recruiting
N/A
150
 
levodopa 4 weeks ;pramipexole 4 weeks ;selegiline 4 weeks
Institute of Psychology, Chinese Academy of Sciences; Peking University Third Hospital, National Natural Science Foundation of China
Parkinson's disease
 
 
ChiCTR1900022534: Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective randomized controlled trial

Not yet recruiting
N/A
388
 
Patients in the entacapone group will be administered entacapone (Novartis; import drug registration certificate number: H20160680), 10 times per day, 200 mg each time, for 3 weeks. ;Patients in the pramipexole group will be administered pramipexole (Boehringer-Ingelheim; import drug registration certificate number: 20140918) , 3 times per day, 1 mg each time, for 3 weeks.
Geriatric Hospital of Hainan; Geriatric Hospital of Hainan, Self-funded
non-motor symptoms of Parkinson’s disease
 
 
ChiCTR1900021708: Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients based on DRD3 Ser9Gly polymorphi

Not yet recruiting
N/A
160
 
No ;pramipexole
Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University; Brain Hospital Affiliated to Nanjing Medical University, China Natural Science Foundation
Parkinson's Disease
 
 
NCT02994719: Gait Analysis in Neurological Disease

Recruiting
N/A
120
US
Anti-Parkinson medication, Carbidopa/levodopa, pramipexole, ropinirole, amantadine, tolcapone, entacapone, Deep Brain Stimulation
Beth Israel Deaconess Medical Center
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease
06/25
06/25
NCT02220309 / 2008-001966-10: Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)

Enrolling by invitation
N/A
160
US
Pramipexole Oral Tablet
Stanford University
Anxiety, Depression
12/24
04/25
ChiCTR2400087756: Efficacy and safety evaluation of generic and original pramipexole: a real-world study

Completed
N/A
1000
 
NA; NA
Xuanwu Hospital of Capital Medical University; Xuanwu Hospital of Capital Medical University, Project commissioned by the National Healthcare Security Administration(JCS-ZCHT-2023-002)
Parkinson’s disease
 
 

Download Options